Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Bile Duct Cancer Treatment, National Cancer Institute.
Source updated: May 24, 2024. Captured 2026-09-09.
Source: Bile Duct Cancer Treatment, National Cancer Institute.
Source updated: May 24, 2024. Captured 2026-09-09.
The following types of surgery are used to treat bile duct cancer:
Removal of the bile duct: This surgical procedure is done to remove part of the bile duct if the tumor is small and is in the bile duct only. Lymph nodes are removed and tissue from the lymph nodes is viewed under a microscope to see if there is cancer.
Sources: bile duct · Lymph nodes
Partial hepatectomy: This is a surgical procedure to remove the part of the liver where cancer is found. The part removed may be a wedge of tissue, an entire lobe, or a larger part of the liver, along with some normal tissue around it.
Whipple procedure: During this surgical procedure the head of the pancreas, the gallbladder, part of the stomach, part of the small intestine, and the bile duct are removed. Enough of the pancreas is left to make digestive juices and insulin.
Sources: pancreas · gallbladder · small intestine · insulin
After the doctor removes all the cancer that can be seen at the time of the surgery, some people may receive chemotherapy or radiation therapy to kill any cancer cells that are left. Treatment given after surgery to lower the risk that the cancer will come back is called adjuvant therapy. It is not yet known whether chemotherapy or radiation therapy given after surgery helps keep the cancer from coming back.
The following types of palliative surgery may be done to relieve symptoms caused by a blocked bile duct and improve quality of life:
Biliary bypass: If cancer is blocking the bile duct and bile is building up in the gallbladder, a biliary bypass may be done. During this operation, the doctor will cut the gallbladder or bile duct in the area before the blockage and sew it to the part of the bile duct that is past the blockage or to the small intestine. This type of surgery creates a new pathway around the blocked area.
Sources: Biliary bypass · bile
Endoscopic stent placement: If the tumor is blocking the bile duct, surgery may be done to put in a stent (a thin, flexible tube) to drain bile that has built up in the area. The doctor may place the stent through a catheter that drains the bile into a bag on the outside of the body or the stent may go around the blocked area and drain the bile into the small intestine.
Sources: catheter
Percutaneous transhepatic biliary drainage: This procedure is used to x-ray the liver and bile ducts. A thin needle is inserted through the skin below the ribs and into the liver. Dye is injected into the liver or bile ducts and an x-ray is taken. If the bile duct is blocked, a stent may be left in the liver to drain bile into the small intestine or a collection bag outside the body.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Bile Duct Cancer Treatment, National Cancer Institute.
Source updated: May 24, 2024. Captured 2026-09-09.
Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. These are the main ways radiation might be given to treat bile duct cancer:
External radiation therapy: A machine outside the body sends radiation toward the area of the body with cancer. Radiation is given in a series of treatments to allow healthy cells to recover and to make radiation more effective. The number of treatments is based on details about the cancer, such as the size and location of the tumor. It is not known whether external radiation therapy helps in the treatment of resectable bile duct cancer. In unresectable, metastatic, or recurrent bile duct cancer, new ways to improve the effect of external radiation therapy on cancer cells are being studied:
Sources: unresectable · metastatic · recurrent
External radiation therapy: A machine outside the body sends radiation toward the area of the body with cancer. Radiation is given in a series of treatments to allow healthy cells to recover and to make radiation more effective. The number of treatments is based on details about the cancer, such as the size and location of the tumor. It is not known whether external radiation therapy helps in the treatment of resectable bile duct cancer. In unresectable, metastatic, or recurrent bile duct cancer, new ways to improve the effect of external radiation therapy on cancer cells are being studied:
Hyperthermia therapy: Body tissue is exposed to high temperatures to make cancer cells more sensitive to the effects of radiation therapy and certain anticancer drugs.
Radiosensitizers: Drugs called radiosensitizers make cancer cells more sensitive to radiation therapy. Combining radiation therapy with radiosensitizers may kill more cancer cells.
Internal radiation therapy: A radioactive substance is sealed in needles, seeds, wires, or catheters that are placed directly into or near the bile duct.
Sources: radioactive · seeds
External and internal radiation therapy are used to treat bile duct cancer and may also be used as palliative therapy to relieve symptoms and improve quality of life.
Sources: palliative therapy
Learn more about Radiation Therapy to Treat Cancer and Radiation Therapy Side Effects.
Sources: Radiation Therapy to Treat Cancer · Radiation Therapy Side Effects
Source: Bile Duct Cancer Treatment, National Cancer Institute.
Source updated: May 24, 2024. Captured 2026-09-09.
Chemotherapy uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. There are two main types of chemotherapy used to treat bile duct cancer.
Systemic chemotherapy: When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body. Systemic chemotherapy is used to treat unresectable, metastatic, or recurrent bile duct cancer. The following chemotherapy drugs may be used:
Systemic chemotherapy: When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body. Systemic chemotherapy is used to treat unresectable, metastatic, or recurrent bile duct cancer. The following chemotherapy drugs may be used:
gemcitabine and cisplatin
Sources: gemcitabine and cisplatin
capecitabine and oxaliplatin (XELOX)
Sources: capecitabine and oxaliplatin (XELOX)
gemcitabine and oxaliplatin (GEMOX)
Sources: gemcitabine and oxaliplatin
gemcitabine and capecitabine
Sources: gemcitabine · capecitabine
Regional chemotherapy: When chemotherapy is placed directly into an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas.Intra-arterial embolization is being studied in the treatment of unresectable, metastatic, or recurrent bile duct cancer. It is a procedure in which the blood supply to a tumor is blocked after anticancer drugs are given in blood vessels near the tumor. Sometimes, the anticancer drugs are attached to small beads that are injected into an artery that feeds the tumor. The beads block blood flow to the tumor as they release the drug. This allows a higher amount of drug to reach the tumor for a longer period of time, which may kill more cancer cells.
Sources: cavity
It is not known whether systemic chemotherapy helps in the treatment of resectable bile duct cancer.
To learn about the different ways chemotherapy works against cancer, what to expect when receiving chemotherapy, and how to manage chemotherapy side effects, see Chemotherapy to Treat Cancer.
Sources: Chemotherapy to Treat Cancer
Source: Bile Duct Cancer Treatment, National Cancer Institute.
Source updated: May 24, 2024. Captured 2026-09-09.
In a liver transplant, the entire liver is removed and replaced with a healthy donated liver. A liver transplant may be done in people with perihilar bile duct cancer. If the person has to wait for a donated liver, other treatment is given as needed.
Sources: perihilar bile duct
Source: Bile Duct Cancer Treatment, National Cancer Institute.
Source updated: May 24, 2024. Captured 2026-09-09.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Your doctor may suggest biomarker tests to help predict your response to certain targeted therapy drugs. Learn more about Biomarker Testing for Cancer Treatment.
Sources: biomarker tests · Biomarker Testing for Cancer Treatment
The following targeted therapy drugs may be used to treat bile duct cancer:
ivosidenib
Sources: ivosidenib
pemigatinib
Sources: pemigatinib
Learn more about Targeted Therapy to Treat Cancer.
Sources: Targeted Therapy to Treat Cancer
Source: Bile Duct Cancer Treatment, National Cancer Institute.
Source updated: May 24, 2024. Captured 2026-09-09.
Immunotherapy helps a person’s immune system fight cancer.
The following immunotherapy drugs may be used to treat bile duct cancer:
durvalumab
Sources: durvalumab
pembrolizumab
Sources: pembrolizumab
Learn more about Immunotherapy to Treat Cancer and Immunotherapy Side Effects.
Sources: Immunotherapy to Treat Cancer · Immunotherapy Side Effects
Source: Bile Duct Cancer Treatment, National Cancer Institute.
Source updated: May 24, 2024. Captured 2026-09-09.
For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trial search · ClinicalTrials.gov
Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.
Sources: Clinical Trials Information for Patients and Caregivers
Source: Bile Duct Cancer Treatment, National Cancer Institute.
Source updated: May 24, 2024. Captured 2026-09-09.
If the cancer has not spread and is in a place where surgery can be safely done, the tumor and some of the tissue around it will be removed. This lowers the chance of the cancer coming back. Chemotherapy with or without radiation therapy may be given after surgery.
Treatment of resectable intrahepatic bile duct cancer may include surgery to remove the cancer. A partial hepatectomy with or without embolization may be done before the surgery.
Sources: intrahepatic bile duct cancer
Treatment of resectable perihilar bile duct cancer may include:
surgery to remove the cancer, which may include partial hepatectomy
stent placement or percutaneous transhepatic biliary drainage, as palliative therapy to relieve jaundice and other symptoms and improve quality of life
Sources: jaundice · quality of life
Treatment of resectable distal bile duct cancer may include:
surgery to remove the cancer, which may include a Whipple procedure
stent placement or percutaneous transhepatic biliary drainage, as palliative therapy to relieve jaundice and other symptoms and improve quality of life
Adjuvant therapy for resectable bile duct cancer may include:
chemotherapy
external-beam radiation therapy
a clinical trial of adjuvant therapy
Source: Bile Duct Cancer Treatment, National Cancer Institute.
Source updated: May 24, 2024. Captured 2026-09-09.
Most people with bile duct cancer cannot have their cancer completely removed with surgery. This may be the case if the cancer has spread too far, the cancer is in a place that is too difficult to completely remove with surgery, or the patient is not healthy enough for surgery.
Treatment of unresectable bile duct cancer (including metastatic or recurrent disease) may include:
stent placement or biliary bypass, as palliative treatment to relieve symptoms and improve quality of life
Sources: quality of life
external or internal radiation therapy, as palliative treatment to relieve symptoms and improve quality of life
systemic chemotherapy
immunotherapy (durvalumab or pembrolizumab) and systemic chemotherapy
Sources: durvalumab · pembrolizumab
targeted therapy with pemigatinib
Sources: pemigatinib
a clinical trial of various combinations of chemotherapy
a clinical trial of immunotherapy or targeted therapy in people with mutations (changes) in certain genes
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
The treatment of bile duct cancer depends primarily on whether the cancer can be completely removed by surgery.
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Localized intrahepatic and extrahepatic bile duct cancer may be completely removed by surgery. These tumors represent a very small number of cases and are usually in the distal common bile duct. Among patients treated with surgical resection, long-term prognosis varies depending on primary tumor extent, margin status, lymph node involvement, and additional pathological features.[1,2]
Extended resections of hepatic duct bifurcation tumors (Klatskin tumors, also known as hilar tumors) to include adjacent liver, either by lobectomy or removal of portions of segments 4 and 5 of the liver, may be performed. If major hepatic resection is necessary to achieve a complete resection, postoperative hepatic reserve should be evaluated. For patients with underlying cirrhosis, the Child-Pugh class and the Model for End-Stage Liver Disease score are determined.
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Most cases of intrahepatic, distal, and perihilar bile duct cancer are unresectable and cannot be completely removed. Often the cancer directly invades the portal vein, the adjacent liver, along the common bile duct, and the adjacent lymph nodes. Portal hypertension may result from invasion of the portal vein. Spread to distant parts of the body is uncommon, but intra-abdominal metastases, particularly peritoneal metastases, do occur. Transperitoneal and hematogenous hepatic metastases also occur with bile duct cancer of all sites. Moreover, most patients who undergo resection will develop recurrent disease within the hepatobiliary system or, less frequently, at distant sites.
In locally advanced disease, phase II trials have evaluated chemoradiotherapy with the goal of improved local control and potential downstaging for surgical resection.[3,4] These approaches have not been compared with standard therapy, and the curative potential is unknown.
For patients with unresectable bile duct cancer, management is directed at palliation.
Treatment options for bile duct cancer are described in Table 16.
Sources: Table 16
| Staging Criteria | Treatment Options |
|---|---|
| Resectable (Localized) Bile Duct Cancer | Surgery |
| Adjuvant therapy | |
| Unresectable (Including Metastatic and Recurrent) Bile Duct Cancer | Palliative therapy |
| Chemotherapy | |
| Immunotherapy | |
| Targeted therapy |
Sources: Surgery · Adjuvant therapy · Palliative therapy · Chemotherapy · Immunotherapy · Targeted therapy
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
The DPYD gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in DPYD, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.[5,6] Patients with the DPYD*2A variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other DPYD variants have been identified, with a range of clinical effects.[5-7] Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on the patient's DPYD genotype and number of functioning DPYD alleles.[8-10] DPYD genetic testing costs less than $200, but insurance coverage varies due to a lack of national guidelines.[11] In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.[12]
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Treatment options for resectable (localized) bile duct cancer include:
Surgery.
Sources: Surgery
Adjuvant therapy.
Sources: Adjuvant therapy
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
For intrahepatic bile duct cancers, hepatic resection to achieve negative margins is potentially curative. If a major liver resection is necessary to achieve negative surgical margins, preoperative portal vein embolization may be considered to optimize the volume of the remnant liver.
Partial liver resection or partial hepatectomy to achieve negative margins is a procedure with curative intent for patients with intrahepatic cholangiocarcinoma.[1] The extent of liver resection necessary depends on the extent of hepatic parenchymal involvement and the proximity of the tumor to major blood vessels in this region.
Sources: 1
The role of routine portal lymphadenectomy has not been well established because of the risk of common bile duct devascularization.
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
For perihilar cholangiocarcinomas (Klatskin tumors), bile duct resection alone leads to high local recurrence rates resulting from the early confluence of the hepatic ducts and the caudate lobe. The addition of partial hepatectomy that includes the caudate lobe has improved long-term outcomes, but it may be associated with increased postoperative complications.[2] With this aggressive surgical approach, 5-year survival rates of 20% to 50% have been reported.[3] An understanding of both the normal and varied vascular and ductal anatomy of the porta hepatis has increased the number of hepatic duct bifurcation tumors that can be resected.
The primary site of relapse after surgical resection is local, but distant recurrence is also frequently reported.[4]
Sources: 4
The optimal surgical procedure for carcinoma of the perihilar bile duct varies according to the location of the tumor along the biliary tree, the extent of hepatic parenchymal involvement, and the proximity of the tumor to major blood vessels in this region. The state of the regional lymph nodes is assessed at the time of surgery because of their prognostic significance. Operations for bile duct cancer are usually extensive. A historical cohort reported an operative mortality rate of approximately 10%, along with a roughly 40% risk of disease recurrence.[5]
Sources: 5
In jaundiced patients, the role of percutaneous transhepatic catheter drainage or endoscopic placement of a stent for relief of biliary obstruction is controversial because of inconsistent findings of significant clinical benefit and concerns of increased risk of postoperative complications.[6] However, percutaneous transhepatic catheter drainage or endoscopic placement of a stent for relief of biliary obstruction may be considered before surgery, particularly if jaundice is severe or an element of azotemia is present.[7,8]
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Complete surgical resection with negative surgical margins offers the only chance of cure for distal bile duct cancers. Bile duct tumors can be difficult to resect because of their proximity to major blood vessels and diffuse infiltration of adjacent bile ducts. Total resection is possible in 25% to 30% of lesions that originate in the distal bile duct. The resectability rate is lower for lesions that occur in more proximal sites.[9]
Sources: 9
The optimum surgical procedure for carcinoma of the distal bile duct will vary according to the location of the tumor along the biliary tree, the extent of hepatic parenchymal involvement, and the proximity of the tumor to major blood vessels in this region. The regional lymph nodes are assessed at the time of surgery because they have prognostic significance. Patients with cancer of the lower end of the duct and regional lymph node involvement may warrant an extensive resection (Whipple procedure). The 5-year survival outcomes range between 20% and 50%.[10,11] Bypass operations or endoluminal stents are alternatives if intraoperatively the tumor is found to be unresectable.[10,11]
In jaundiced patients, the role of percutaneous transhepatic catheter drainage or endoscopic placement of a stent for relief of biliary obstruction is controversial, but these options may be considered before surgery, particularly if jaundice is severe or an element of azotemia is present.[7,8]
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Numerous retrospective series have suggested that adjuvant chemotherapy after complete surgical resection may be beneficial.[12,13][Level of evidence C2] However, prospective randomized trials have failed to consistently show a significant benefit in overall survival (OS).
Sources: 12 · 13 · Level of evidence C2
Evidence (chemotherapy):
A multicenter phase III study in the United Kingdom (BILCAP) included 447 patients with cholangiocarcinoma or muscle-invasive gallbladder cancer who underwent a macroscopically complete resection with curative intent. Patients were randomly assigned to receive eight cycles of capecitabine (1,250 mg/m2 twice a day on days 1−14 of a 21-day cycle) or observation.[13][Level of evidence B1] At a median follow-up of 106 months, the following results were observed:
Sources: 13 · Level of evidence B1
A multicenter phase III study in the United Kingdom (BILCAP) included 447 patients with cholangiocarcinoma or muscle-invasive gallbladder cancer who underwent a macroscopically complete resection with curative intent. Patients were randomly assigned to receive eight cycles of capecitabine (1,250 mg/m2 twice a day on days 1−14 of a 21-day cycle) or observation.[13][Level of evidence B1] At a median follow-up of 106 months, the following results were observed:
There was no statistically significant difference in OS in the intention-to-treat analysis (median OS, 49.6 months in the capecitabine group vs. 36.1 months in the observation group; adjusted hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.67−1.06; P > .05).
In the intention-to-treat analysis, the median recurrence-free survival (RFS) was 24.3 months (95% CI, 18.6–34.6) in the capecitabine group and 17.4 months (95% CI, 11.8–23) in the observation group. An adjusted Cox proportional hazards model suggested potential improvement in RFS in the first 24 months from randomization (HR, 0.74; 95% CI, 0.57–0.96), but with no significant difference in the period after 24 months (HR, 1.57; 95% CI, 0.90–2.74).
The open-label, randomized, phase II STAMP study (NCT03079427), presented in abstract form, included 101 patients with perihilar or distal bile duct cancer, at least one regional lymph node metastasis (N1 or greater), and complete macroscopic (R0 or R1) resection within 12 weeks. Patients were assigned to receive either eight cycles of capecitabine (1,250 mg/m2) twice a day on days 1–14 of a 21-day cycle (based on the BILCAP trial) or eight cycles of cisplatin (25 mg/m2) and gemcitabine (1,000 mg/m2) on days 1 and 8 of a 21-day cycle. The primary end point was disease-free survival (DFS).[14][Level of evidence B1] At a median follow-up of 28.7 months, the following results were observed:
Sources: STAMP · 14 · Level of evidence B1
The open-label, randomized, phase II STAMP study (NCT03079427), presented in abstract form, included 101 patients with perihilar or distal bile duct cancer, at least one regional lymph node metastasis (N1 or greater), and complete macroscopic (R0 or R1) resection within 12 weeks. Patients were assigned to receive either eight cycles of capecitabine (1,250 mg/m2) twice a day on days 1–14 of a 21-day cycle (based on the BILCAP trial) or eight cycles of cisplatin (25 mg/m2) and gemcitabine (1,000 mg/m2) on days 1 and 8 of a 21-day cycle. The primary end point was disease-free survival (DFS).[14][Level of evidence B1] At a median follow-up of 28.7 months, the following results were observed:
The median DFS was 14.3 months (1-sided 90% CI, 10.7–16.5) in the cisplatin-and-gemcitabine group and 11.1 months in the capecitabine group (1-sided 90% CI, 8.4–12.7).
The median OS was 35.7 months (1-sided 90% CI, 29.5–not estimated) in the cisplatin-and-gemcitabine group and 35.7 months (1-sided 90% CI, 30.9–not estimated) in the capecitabine group.
The gemcitabine-and-cisplatin group had increased rates of toxicity. Grade 3 to 4 adverse events occurred in 84% of patients who received gemcitabine and cisplatin (most commonly neutropenia) and in 16% of patients who received capecitabine (most commonly hand-foot syndrome).
Given the lack of significant difference in DFS and OS and the higher toxicity rate in the cisplatin-and-gemcitabine group, capecitabine remains the reference standard for adjuvant therapy.
A French multicenter phase III study (PRODIGE 12-ACCORD 18-UNICANCER GI) randomly assigned 196 patients with R0 or R1 resection of localized biliary tract cancer to 12 cycles of adjuvant gemcitabine plus oxaliplatin (GEMOX) or surveillance. The primary end point was RFS, and the secondary end point was OS.[15][Level of evidence B1] After a median follow-up of 46.5 months the following results were observed:
Sources: 15 · Level of evidence B1
A French multicenter phase III study (PRODIGE 12-ACCORD 18-UNICANCER GI) randomly assigned 196 patients with R0 or R1 resection of localized biliary tract cancer to 12 cycles of adjuvant gemcitabine plus oxaliplatin (GEMOX) or surveillance. The primary end point was RFS, and the secondary end point was OS.[15][Level of evidence B1] After a median follow-up of 46.5 months the following results were observed:
There was no statistically significant difference in RFS (median, 30.4 months with GEMOX vs. 18.5 months with observation; HR, 0.88; 95% CI, 0.62–1.25, P = .48).
There was also no statistically significant difference in OS (75.8 months with GEMOX vs. 50.8 months with observation; HR, 1.08; 95% CI, 0.7–1.66; P = .74).
The Bile Duct Cancer Adjuvant Trial (BCAT), a Japanese, multicenter, phase III study, included 225 patients with resected bile duct cancer. Patients were randomly assigned to six cycles of adjuvant gemcitabine or observation. The primary end point was OS, and the secondary end point was RFS.[16][Level of evidence B1]
Sources: 16 · Level of evidence B1
The Bile Duct Cancer Adjuvant Trial (BCAT), a Japanese, multicenter, phase III study, included 225 patients with resected bile duct cancer. Patients were randomly assigned to six cycles of adjuvant gemcitabine or observation. The primary end point was OS, and the secondary end point was RFS.[16][Level of evidence B1]
There was no significant difference in OS (median, 62.3 months with gemcitabine vs. 63.8 months with observation; HR, 1.01; 95% CI, 0.7–1.45; P = .964).
No OS differences were observed, even in subgroups stratified by lymph node status and surgical margin status.
There was also no significant difference in RFS (median, 36 months with gemcitabine vs. 39.9 months with observation; HR, 0.93; P = .693).
The European Study Group for Pancreatic Cancer (ESPAC-3 trial [NCT00058201]) enrolled 428 patients with periampullary cancer, which included 96 patients with bile duct cancers. Patients were randomly assigned to observation, 6 months of fluorouracil (5-FU)/leucovorin, or 6 months of gemcitabine.[17][Level of evidence B1]
Sources: ESPAC-3 · 17 · Level of evidence B1
The European Study Group for Pancreatic Cancer (ESPAC-3 trial [NCT00058201]) enrolled 428 patients with periampullary cancer, which included 96 patients with bile duct cancers. Patients were randomly assigned to observation, 6 months of fluorouracil (5-FU)/leucovorin, or 6 months of gemcitabine.[17][Level of evidence B1]
Among all patients, adjuvant chemotherapy was not associated with significant OS benefit when compared with observation. However, after adjusting for prognostic variables by multivariable analysis, a statistically significant OS benefit was associated with adjuvant chemotherapy (HR, 0.75; 95% CI, 0.57–0.98; P = .03).
In a preplanned subgroup analysis of the 96 patients with bile duct cancer, no benefit was seen among patients treated with chemotherapy. Limitations of this subgroup analysis include limited statistical power and difficulty in differentiating ampullary versus distal common bile duct tumors as the pathological site of origin.
The median survival was 27 months for the observation-alone group, 18 months for the 5-FU-leucovorin group, and 20 months for the gemcitabine-alone group.[17]
Sources: 17
A multi-institutional Japanese study compared surgery alone with mitomycin and infusional 5-FU followed by 5-FU until disease progression.[18][Level of evidence B1]
Sources: 18 · Level of evidence B1
A multi-institutional Japanese study compared surgery alone with mitomycin and infusional 5-FU followed by 5-FU until disease progression.[18][Level of evidence B1]
Among the subset of patients with bile duct cancer (n = 139), no survival benefit was seen.
For a list of chemotherapy regimens with potential activity, see the Treatment of Unresectable (Including Metastatic and Recurrent) Bile Duct Cancer section.
Sources: Treatment of Unresectable (Including Metastatic and Recurrent) Bile Duct Cancer
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Numerous retrospective studies have suggested that adding EBRT after complete surgical resection may be beneficial.[19,20][Level of evidence A1] However, no prospective randomized trials have demonstrated an OS benefit.
Sources: 19 · 20 · Level of evidence A1
Evidence (EBRT):
One small randomized trial of 207 patients with pancreatic and periampullary cancers demonstrated no survival benefit of adding chemoradiation therapy after surgery. This study had limitations: only a few patients had a diagnosis of bile duct cancer, and 20% of the patients randomly assigned to receive chemoradiation therapy did not receive treatment.[21][Level of evidence C3]
Sources: 21 · Level of evidence C3
A phase II cooperative group trial, SWOG S0809 (NCT00789958), evaluated adjuvant capecitabine and gemcitabine followed by chemoradiation therapy for resected extrahepatic cholangiocarcinoma and gallbladder cancer. In total, 79 eligible patients with pT2 to pT4 disease, node-positive disease, or positive-margin resection were enrolled (extrahepatic bile duct cancer, n = 54; gallbladder cancer, n = 25).[22][Level of evidence C2]
Sources: SWOG S0809 · 22 · Level of evidence C2
A phase II cooperative group trial, SWOG S0809 (NCT00789958), evaluated adjuvant capecitabine and gemcitabine followed by chemoradiation therapy for resected extrahepatic cholangiocarcinoma and gallbladder cancer. In total, 79 eligible patients with pT2 to pT4 disease, node-positive disease, or positive-margin resection were enrolled (extrahepatic bile duct cancer, n = 54; gallbladder cancer, n = 25).[22][Level of evidence C2]
The 2-year survival rate of 65% was significantly higher than expected, based on historical controls.[22][Level of evidence C2]
Sources: 22 · Level of evidence C2
Grade 3 toxicity was observed in 52% of patients, and grade 4 toxicity was observed in 11% of patients.
Based on these results, this regimen was observed to be well tolerated, but it needs to be tested in a randomized controlled trial.
All patients are encouraged to enroll in clinical trials for adjuvant therapies. Information about ongoing clinical trials is available from the NCI website.
Sources: NCI website
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Treatment options for unresectable (including metastatic and recurrent) bile duct cancer include:
Palliative therapy.
Sources: Palliative therapy
Chemotherapy.
Sources: Chemotherapy
Immunotherapy.
Sources: Immunotherapy
Targeted therapy.
Sources: Targeted therapy
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Relief of biliary obstruction is warranted when symptoms such as pruritus and hepatic dysfunction outweigh other symptoms of the cancer. When possible, such palliation can be achieved with the placement of bile duct stents by operative, endoscopic, or percutaneous techniques.[1,2]
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Systemic chemotherapy is appropriate for selected patients with adequate performance status and intact organ function.
Evidence (chemotherapy):
The phase III ABC-02 study (NCT00262769) randomly assigned 410 patients with unresectable, recurrent, or metastatic biliary tract carcinoma to receive either cisplatin plus gemcitabine or gemcitabine alone for up to 6 months.[5][Level of evidence A1]
Sources: ABC-02 · 5 · Level of evidence A1
The phase III ABC-02 study (NCT00262769) randomly assigned 410 patients with unresectable, recurrent, or metastatic biliary tract carcinoma to receive either cisplatin plus gemcitabine or gemcitabine alone for up to 6 months.[5][Level of evidence A1]
The median overall survival (OS) was prolonged in the cisplatin-gemcitabine group (11.7 months) compared with the gemcitabine-alone group (8.1 months) (hazard ratio [HR], 0.64; 95% confidence interval [CI], 0.52−0.80; P < .001).[5]
Sources: 5
A similar median OS benefit was demonstrated in all subgroups, including 73 patients with extrahepatic bile duct cancer and 57 patients with hilar tumors.
Grades 3 and 4 toxicities occurred with similar frequencies in both study groups, with the exception of increased hematologic toxicity in the cisplatin-gemcitabine group and increased hepatic toxicity in the gemcitabine-alone group.
A phase II study (NCT03044587) included 91 patients with advanced cholangiocarcinoma. Patients were randomly assigned to receive the combination of liposomal irinotecan, 5-fluorouracil (5-FU), and leucovorin (arm A) or the ABC-02 study regimen of cisplatin plus gemcitabine (arm B). The primary end point was a prespecified benchmark of a 4-month progression-free survival (PFS) rate of 40%.[6][Level of evidence B3]
Sources: NCT03044587 · 6 · Level of evidence B3
A phase II study (NCT03044587) included 91 patients with advanced cholangiocarcinoma. Patients were randomly assigned to receive the combination of liposomal irinotecan, 5-fluorouracil (5-FU), and leucovorin (arm A) or the ABC-02 study regimen of cisplatin plus gemcitabine (arm B). The primary end point was a prespecified benchmark of a 4-month progression-free survival (PFS) rate of 40%.[6][Level of evidence B3]
The 4-month PFS rate was 51% in arm A. The median PFS was 6 months (95% CI, 2.4–9.6) in arm A and 6.9 months (95% CI, 2.5–7.9) in arm B.
The median OS was 15.9 months (95% CI, 10.6–20.3) in arm A and 13.6 months (95% CI, 6.5–17.7) in arm B.
A phase III noninferiority study (NCT01470443) enrolled 114 patients with metastatic biliary tract cancers, including 30 (26%) with primary gallbladder cancer. Patients were randomly assigned to receive capecitabine plus oxaliplatin (XELOX) or gemcitabine plus oxaliplatin (GEMOX). The primary end point was 6-month PFS.[7][Level of evidence B1]
Sources: NCT01470443 · 7 · Level of evidence B1
A phase III noninferiority study (NCT01470443) enrolled 114 patients with metastatic biliary tract cancers, including 30 (26%) with primary gallbladder cancer. Patients were randomly assigned to receive capecitabine plus oxaliplatin (XELOX) or gemcitabine plus oxaliplatin (GEMOX). The primary end point was 6-month PFS.[7][Level of evidence B1]
OS was not significantly different between treatment groups. It was 10.4 months (95% CI, 8.0−12.6) in the GEMOX group and 10.6 months (95% CI, 7.3−15.5) in the XELOX group (P = .131).
The PFS rate was 44.6% in the GEMOX group and 46.7% in the XELOX group (95% CI of difference in 6-month PFS rate, -12% to 16%, meeting criteria for noninferiority).
A predefined subgroup analysis based on primary site of disease did not reveal a difference in objective response rate between the two arms in patients with gallbladder cancer (P = .598).
Pending further clinical trials, cisplatin plus gemcitabine is considered the reference standard first-line chemotherapy backbone for patients with unresectable, metastatic, or recurrent bile duct cancer. Following the results of the TOPAZ-1 and KEYNOTE-966 trials, addition of a checkpoint inhibitor (either durvalumab or pembrolizumab) to front-line therapy has become the standard of care (for more information, see the Immunotherapy section). Potential alternatives include 5-FU plus liposomal irinotecan, gemcitabine plus capecitabine, GEMOX, and XELOX. All patients should consider clinical trials.
Sources: Immunotherapy
There is limited high-quality evidence to guide selection of a second-line regimen in refractory disease:
A multicenter phase III trial in the United Kingdom (ABC-06 [NCT01926236]) included 162 patients with locally advanced or metastatic biliary tract cancer and documented radiological disease progression on first-line cisplatin and gemcitabine. Patients were randomly assigned to receive either FOLFOX (folinic acid, 5-FU, and oxaliplatin) with active symptom control (ASC) or ASC alone. The following results were observed after a median follow-up of 21.7 months:[8][Level of evidence A1]Two phase II trials have evaluated 5-FU and leucovorin with or without liposomal irinotecan, but results differed.
Sources: ABC-06 · 8 · Level of evidence A1
A multicenter phase III trial in the United Kingdom (ABC-06 [NCT01926236]) included 162 patients with locally advanced or metastatic biliary tract cancer and documented radiological disease progression on first-line cisplatin and gemcitabine. Patients were randomly assigned to receive either FOLFOX (folinic acid, 5-FU, and oxaliplatin) with active symptom control (ASC) or ASC alone. The following results were observed after a median follow-up of 21.7 months:[8][Level of evidence A1]Two phase II trials have evaluated 5-FU and leucovorin with or without liposomal irinotecan, but results differed.
The median OS was significantly longer in the FOLFOX group (6.2 months) than in the ASC-alone group (5.3 months) (adjusted HR, 0.69; 95% CI, 0.50−0.97; P = .031). In the FOLFOX group, the OS rate was 50.6% at 6 months and 25.9% at 12 months, compared with 35.5% at 6 months and 11.4% at 12 months in the ASC-alone group.
Grade 3 to 5 adverse events were reported in 56 patients (69%) in the FOLFOX group, compared with 42 patients (52%) in the ASC-alone group. The most frequently reported grade 3 to 5 FOLFOX-related adverse events were neutropenia (12%), fatigue/lethargy (11%), and infection (10%). There were three chemotherapy-related deaths, one each due to infection, acute kidney injury, and febrile neutropenia.
A multicenter phase IIb trial in South Korea (NIFTY [NCT03524508]) randomly assigned 174 patients with metastatic biliary tract cancer that had progressed during first-line cisplatin and gemcitabine to receive 5-FU and leucovorin with or without liposomal irinotecan. The following was observed after a median follow-up of 6.1 months:[9][Level of evidence A1]
Sources: NIFTY · 9 · Level of evidence A1
A multicenter phase IIb trial in South Korea (NIFTY [NCT03524508]) randomly assigned 174 patients with metastatic biliary tract cancer that had progressed during first-line cisplatin and gemcitabine to receive 5-FU and leucovorin with or without liposomal irinotecan. The following was observed after a median follow-up of 6.1 months:[9][Level of evidence A1]
The primary end point of median PFS was significantly longer in the group who received liposomal irinotecan (3.9 months) compared with the group who received 5-FU plus leucovorin alone (1.6 months) (HR, 0.38; 95% CI, not reported; P = .0001). A secondary end point of median OS was also significantly longer in the group who received liposomal irinotecan (8.6 months) compared with the group who received 5-FU plus leucovorin alone (5.3 months) (HR, 0.68; 95% CI, not reported; P = .024).
The German multicenter phase II NALIRICC trial (NCT03043547) included 100 patients with metastatic biliary tract cancer that progressed during gemcitabine-based therapy. Patients were randomly assigned to receive 5-FU plus leucovorin with or without liposomal irinotecan.[10][Level of evidence A1]
Sources: NALIRICC · 10 · Level of evidence A1
The German multicenter phase II NALIRICC trial (NCT03043547) included 100 patients with metastatic biliary tract cancer that progressed during gemcitabine-based therapy. Patients were randomly assigned to receive 5-FU plus leucovorin with or without liposomal irinotecan.[10][Level of evidence A1]
The median PFS in the liposomal irinotecan group was 2.6 months, compared with 2.3 months in the 5-FU–leucovorin-alone group (HR, 0.87; 95% CI, 0.56–1.35; P not reported). The median OS was 6.9 months in the liposomal irinotecan group and 8.2 months in the 5-FU–leucovorin-alone group (HR, 1.08; 95% CI, 0.68–1.72; P not reported).
Toxicity was significantly higher in the liposomal irinotecan group, with treatment-related serious adverse events occurring in 16 patients (33%), compared with one patient (2%) in the 5-FU–leucovorin-alone group. The most common grade 3 or higher adverse events in the liposomal irinotecan group were neutropenia (17%), diarrhea (15%), and nausea (8%).
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Based on results from the TOPAZ-1 and KEYNOTE-966 trials, all patients with unresectable, metastatic, or recurrent disease should consider treatment with a checkpoint inhibitor (either durvalumab or pembrolizumab) with cisplatin and gemcitabine (the previous standard-of-care doublet) in the first-line setting.[11-13]
Evidence (immunotherapy):
An international, multicenter, phase III study (TOPAZ-1 [NCT03875235]) included 685 patients with locally advanced, recurrent, or metastatic biliary tract cancer that was unresectable and previously untreated. Patients were randomly assigned to receive either durvalumab or placebo with cisplatin plus gemcitabine for up to eight cycles, followed by durvalumab or placebo maintenance until disease progression or unacceptable toxicity occurred. The primary end point was OS. After a median follow-up of 23.4 months for patients in the durvalumab arm, the following results were observed:[12,13]
An international, multicenter, phase III study (TOPAZ-1 [NCT03875235]) included 685 patients with locally advanced, recurrent, or metastatic biliary tract cancer that was unresectable and previously untreated. Patients were randomly assigned to receive either durvalumab or placebo with cisplatin plus gemcitabine for up to eight cycles, followed by durvalumab or placebo maintenance until disease progression or unacceptable toxicity occurred. The primary end point was OS. After a median follow-up of 23.4 months for patients in the durvalumab arm, the following results were observed:[12,13]
The median OS was significantly improved in the durvalumab group (12.9 months) compared with the placebo group (11.3 months) (HR, 0.76; 95% CI, 0.64–0.91). In the durvalumab group, the 18-month OS rate was 35.1% and the 24-month OS rate was 24.9%. In the placebo group, the 18-month OS rate was 25.5% and the 24-month OS rate was 10.4%.[12,13][Level of evidence A1]
Sources: 12 · 13 · Level of evidence A1
There was no significant difference between groups in the number of grade 3 or 4 treatment-related adverse events or the number of events leading to discontinuation of a study medication.
An international, multicenter, phase III study (KEYNOTE-966 [NCT04003636]) enrolled 1,069 patients with previously untreated, unresectable, locally advanced or metastatic biliary tract cancer. Patients were randomly assigned to receive either pembrolizumab or placebo for up to 35 cycles. This was combined with gemcitabine (with no maximum duration) and cisplatin for up to 8 cycles. After a median follow-up of 25.6 months, the following results were observed:[11][Level of evidence A1]
Sources: KEYNOTE-966 · 11 · Level of evidence A1
An international, multicenter, phase III study (KEYNOTE-966 [NCT04003636]) enrolled 1,069 patients with previously untreated, unresectable, locally advanced or metastatic biliary tract cancer. Patients were randomly assigned to receive either pembrolizumab or placebo for up to 35 cycles. This was combined with gemcitabine (with no maximum duration) and cisplatin for up to 8 cycles. After a median follow-up of 25.6 months, the following results were observed:[11][Level of evidence A1]
The median OS was 12.7 months in the pembrolizumab group and 10.9 months in the placebo group (HR, 0.83; 95% CI, 0.72–0.95; one-sided P = .0034).
There was no difference in the total frequency of treatment-related adverse events between treatment groups, including grade 3 or grade 4 events. Death due to treatment-related adverse events was seen in a total of eight patients (2%) in the pembrolizumab arm and three patients (1%) in the placebo arm.
All patients with unresectable, metastatic, or recurrent disease who have not already received a checkpoint inhibitor should have molecular testing for deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) tumors. Extrapolating from a subgroup of patients with gastrointestinal and hepatopancreatobiliary tumors in the I-PREDICT (NCT02534675) and KEYNOTE-158 (NCT02628067) studies, patients with either dMMR or MSI-H tumors can consider pembrolizumab treatment.[14,15][Level of evidence C3]
Sources: I-PREDICT · KEYNOTE-158 · 14 · 15 · Level of evidence C3
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Patients with targetable pathogenic variants can consider clinical trials of investigational therapies. Currently, targeted therapies have only been approved for patients whose disease has progressed or who are ineligible for first-line therapies.
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
Up to 15% of bile duct cancers have IDH1 variants.
Evidence (IDH1 inhibitors):
The phase III ClarIDHy trial (NCT02989857) included 187 patients with cholangiocarcinoma and IDH1 variants. Patients had disease that had progressed during previous systemic therapy. Patients were randomly assigned to receive either the IDH1 inhibitor ivosidenib or placebo. The primary end point was PFS.[16,17][Level of evidence B1]
Sources: ClarIDHy · 16 · 17 · Level of evidence B1
The phase III ClarIDHy trial (NCT02989857) included 187 patients with cholangiocarcinoma and IDH1 variants. Patients had disease that had progressed during previous systemic therapy. Patients were randomly assigned to receive either the IDH1 inhibitor ivosidenib or placebo. The primary end point was PFS.[16,17][Level of evidence B1]
The median PFS was improved among patients treated with ivosidenib (2.7 months) compared with placebo (1.4 months) (HR, 0.37; 95% CI, 0.25−0.54; P < .001). PFS rates at 6 months and 12 months were 32% and 21.9%, respectively, in the ivosidenib arm. No patients in the placebo group were progression free at 6 months.
In the intention-to-treat analysis, median OS was 10.3 months in the ivosidenib group compared with 7.5 months for the placebo group (HR, 0.79; one-sided P = .09), despite crossover of 57% of placebo patients to ivosidenib. When adjusted for crossover, median OS for the placebo group was 5.1 months.
Grades 3 and 4 toxicities occurred in 46% of patients in the ivosidenib group and 36% of patients in the placebo group.
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
FGFR2 gene fusions are present in approximately 15% of intrahepatic cholangiocarcinomas. Multiple phase II trials, some reported in abstract form, have suggested activity of FGFR inhibitors in patients with cholangiocarcinoma and FGFR2 fusions whose disease progressed after or who were ineligible for first-line chemotherapy.[18,19]
Evidence (FGFR inhibitors):
The multicenter, open-label, single-arm phase II FIGHT-202 trial (NCT02924376) enrolled 147 patients with disease progression during or after at least one previous therapy. A total of 108 patients had FGFR2 rearrangements or fusions. All patients received 13.5 mg of pemigatinib orally once daily for 14 consecutive days, followed by 7 days off therapy. At a median follow-up of 45.4 months, the following results were observed:[20][Level of evidence C3]In 2020, the FDA granted accelerated approval of pemigatinib for the treatment of adults with previously treated unresectable or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement.
Sources: FIGHT-202 · 20 · Level of evidence C3
The multicenter, open-label, single-arm phase II FIGHT-202 trial (NCT02924376) enrolled 147 patients with disease progression during or after at least one previous therapy. A total of 108 patients had FGFR2 rearrangements or fusions. All patients received 13.5 mg of pemigatinib orally once daily for 14 consecutive days, followed by 7 days off therapy. At a median follow-up of 45.4 months, the following results were observed:[20][Level of evidence C3]In 2020, the FDA granted accelerated approval of pemigatinib for the treatment of adults with previously treated unresectable or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement.
The overall response rate in the cohort of patients with FGFR2 rearrangements/fusions was 37% (95% CI, 27.9%−46.9%), including three complete responses. Among the 40 patients who achieved an objective response, the median duration of response was 9.1 months (95% CI, 6.0–14.5).
The median PFS in patients with FGFR2 rearrangements or fusions was 7.0 months (95% CI, 6.1–10.5), and the median OS was 17.5 months (95% CI, 14.4–22.9). Given the single-arm study design, the relative effect of pemigatinib on PFS and OS was not established. However, in the cohort of study patients whose tumors did not harbor FGFR rearrangements, the median PFS was only 1.5 months and the median OS was only 4.0 months.
The most common adverse effect was hyperphosphatemia, occurring in 58.5% of patients, although no adverse effect was grade 3 or higher. Adverse events led to treatment discontinuation in 10.2% of patients, dose reduction in 13.64% of patients, and dose interruptions in 42.2% of patients.
Futibatinib is an irreversible noncompetitive inhibitor of FGFR1–4. Preclinical in vitro studies showed that futibatinib was less susceptible to on-target resistance variants than pemigatinib. However, there are no head-to-head clinical trial data comparing outcomes for the various FGFR inhibitors. The multinational, open-label, single-group, phase II FOENIX-CCA2 trial (NCT02052778) evaluated futibatinib in patients with previously treated intrahepatic cholangiocarcinoma and FGFR2 fusions or rearrangements. The study enrolled 103 patients with disease progression after at least one previous line of systemic therapy. All patients received futibatinib at a continuous dose of 20 mg once daily.[21][Level of evidence C3]
Sources: FOENIX-CCA2 · 21 · Level of evidence C3
Futibatinib is an irreversible noncompetitive inhibitor of FGFR1–4. Preclinical in vitro studies showed that futibatinib was less susceptible to on-target resistance variants than pemigatinib. However, there are no head-to-head clinical trial data comparing outcomes for the various FGFR inhibitors. The multinational, open-label, single-group, phase II FOENIX-CCA2 trial (NCT02052778) evaluated futibatinib in patients with previously treated intrahepatic cholangiocarcinoma and FGFR2 fusions or rearrangements. The study enrolled 103 patients with disease progression after at least one previous line of systemic therapy. All patients received futibatinib at a continuous dose of 20 mg once daily.[21][Level of evidence C3]
The overall response rate was 42% (95% CI, 31.1%–50.4%), including one complete response. Of the patients who had a response, the median duration of response was 9.7 months.
The median PFS was 9 months (95% CI, 6.9–13.1), and the median OS was 21.7 months (95% CI 14.5–NR). Given the single-arm study design, the relative effect of futibatinib on PFS and OS has not yet been established.
The most common adverse effect of any grade was hyperphosphatemia, which occurred in 85% of patients and was grade 3 in 30% of patients. Other common adverse effects included alopecia (33%), dry mouth (30%), dry skin (27%), and fatigue (25%). Other notable grade 3 toxicities included aspartate aminotransferase elevation (7%) and stomatitis (6%). Treatment-related adverse events led to dose interruptions in 50% of patients, dose reductions in 54% of patients, and permanent drug discontinuation in 2% of patients.
Patients with FGFR2 fusion−positive disease should be encouraged to enroll in a clinical trial.
Source: Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025. Captured 2026-09-09.
The international, multicenter, single-arm, phase IIb HERIZON-BTC-01 trial (NCT04466891) enrolled 87 patients with HER2-amplified (by fluorescence in situ hybridization), unresectable, locally advanced or metastatic biliary tract cancer whose disease progressed on prior gemcitabine-based therapy. Cohort 1 included 80 patients with HER2 2+ or 3+ expression by immunohistochemistry (IHC), while cohort 2 included seven patients with HER2 0+ or 1+ expression by IHC. All patients received zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, at a dose of 20 mg/kg intravenously every 2 weeks. At a median follow-up of 12.4 months, the following results were observed:[22][Level of evidence C3]
Sources: HERIZON-BTC-01 · 22 · Level of evidence C3
The international, multicenter, single-arm, phase IIb HERIZON-BTC-01 trial (NCT04466891) enrolled 87 patients with HER2-amplified (by fluorescence in situ hybridization), unresectable, locally advanced or metastatic biliary tract cancer whose disease progressed on prior gemcitabine-based therapy. Cohort 1 included 80 patients with HER2 2+ or 3+ expression by immunohistochemistry (IHC), while cohort 2 included seven patients with HER2 0+ or 1+ expression by IHC. All patients received zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, at a dose of 20 mg/kg intravenously every 2 weeks. At a median follow-up of 12.4 months, the following results were observed:[22][Level of evidence C3]
In cohort 1, the objective response rate was 41.3% (95% CI, 30.4%–52.8%). The median duration of response was 12.9 months (95% CI, 6.0–not reached).
The median PFS was 5.5 months in cohort 1 (95% CI, 3.7–7.2) and 1.9 months (95% CI, 1.2–not estimable) in cohort 2.
Serious treatment-related adverse events occurred in 8% of patients. Zanidatamab was discontinued in two patients: one due to reduced ejection fraction and one due to pneumonitis. Diarrhea (37%) and infusion reactions with the first cycle (33%) were relatively common, but mostly low-grade.
The FDA has granted breakthrough therapy designation for zanidatamab in this setting, but it is not yet FDA approved.
Although not FDA approved specifically for biliary tract cancer, a growing body of evidence demonstrated activity of the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-expressing solid tumors.
The DESTINY-PanTumor02 trial (NCT04482309), reported in abstract form, was tumor-agnostic (enrolled patients with HER2-positive tumors from any site) but included a subset of 41 patients with biliary tract cancer.[23][Level of evidence C3]
Sources: DESTINY-PanTumor02 · 23 · Level of evidence C3
The DESTINY-PanTumor02 trial (NCT04482309), reported in abstract form, was tumor-agnostic (enrolled patients with HER2-positive tumors from any site) but included a subset of 41 patients with biliary tract cancer.[23][Level of evidence C3]
The overall response rate was 22% in this subset of patients.
The phase II HERB trial (NCT04482309) enrolled 32 patients (24 with HER2-positive disease, 8 with HER2-low disease) with biliary tract cancers refractory to, or intolerant of, a gemcitabine-containing regimen. All patients received trastuzumab deruxtecan.[24][Level of evidence C3]
Sources: HERB · 24 · Level of evidence C3
The phase II HERB trial (NCT04482309) enrolled 32 patients (24 with HER2-positive disease, 8 with HER2-low disease) with biliary tract cancers refractory to, or intolerant of, a gemcitabine-containing regimen. All patients received trastuzumab deruxtecan.[24][Level of evidence C3]
Among the patients with HER2-positive disease, the overall response rate was 36.4%. The median PFS was 5.1 months (95% CI, 3.0–7.3), and the median OS was 7.1 months (95% CI, 4.7–14.6).
Among the small sample of eight patients with HER2-low disease, the overall response rate was 12.5%. The median PFS was 3.5 months (95% CI, 1.2–5.5), and the median OS was 8.9 months (95% CI, 3.0–12.8).
Similarly, the combination of tucatinib and trastuzumab—which the FDA has not approved for the treatment of biliary tract cancer but has approved for breast and colorectal cancer indications—was shown to have potential activity in previously treated patients.
The tumor-agnostic phase II SGNTUC-019 study (NCT04579380) evaluated the combination of tucatinib and trastuzumab. The trial included a cohort of 30 patients with previously treated HER2-overexpressing or HER2-amplified biliary tract cancer.[25][Level of evidence C3]
Sources: SGNTUC-019 · 25 · Level of evidence C3
The tumor-agnostic phase II SGNTUC-019 study (NCT04579380) evaluated the combination of tucatinib and trastuzumab. The trial included a cohort of 30 patients with previously treated HER2-overexpressing or HER2-amplified biliary tract cancer.[25][Level of evidence C3]
At a median follow-up of 10.8 months, the objective response rate was 46.7% (90% CI, 30.8%–63.0%), with a disease control rate of 76.7% (90% CI, 60.6%–88.5%).
The median PFS was 5.5 months (90% CI, 3.9–8.2).
The most common treatment-related adverse events were pyrexia (43.3%) and diarrhea (40%). Adverse events caused no deaths but led one patient to discontinue treatment.
Patients with HER2-amplified disease are candidates for clinical trials.
All patients are encouraged to enroll in clinical trials for adjuvant therapies. Information about ongoing clinical trials is available from the NCI website.
Sources: NCI website
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
ClinicalTrials.gov recordExtrahepatic Bile Duct Cancer, Gallbladder Cancer
ClinicalTrials.gov recordBiliary Tract Cancer, Gallbladder Cancer, Cholangiocarcinoma, Ampullary Cancer
ClinicalTrials.gov recordCholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, Primary CNS Tumors, Breast Cancer, Gastric Cancer
ClinicalTrials.gov recordCholangiocarcinoma
ClinicalTrials.gov recordAdvanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma
ClinicalTrials.gov recordCholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic, Cholangiocarcinoma of the Gallbladder, Cholangiocarcinoma Advanced
ClinicalTrials.gov recordAdenocarcinoma Metastatic, Biliary Tract Cancer, Adenocarcinoma of the Biliary Tract, Adenocarinoma Locally Advanced, Non-Resectable Hepatocellular Carcinoma, Intrahepatic Bile...
ClinicalTrials.gov recordCholangiocarcinoma, Biliary Tract Cancer, Adjuvant Chemotherapy, Capecitabine, Gemcitabine, Cisplatin
ClinicalTrials.gov recordMetastatic Biliary Tract Cancer
ClinicalTrials.gov recordHER2-amplified Biliary Tract Cancers
ClinicalTrials.gov recordUterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
ClinicalTrials.gov recordColorectal Cancer, Depression, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Fatigue, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer
ClinicalTrials.gov recordAdult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma, Hilar...
ClinicalTrials.gov recordBile Duct Cancer (Cholangiocarcinoma)
Treatment of resectable (localized) bile duct cancer
Adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements
Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
Treatment of unresectable bile duct cancer (including metastatic or recurrent disease)
Treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangement as detected by an FDA approved test
PEMAZYRE is a kinase inhibitor indicated: for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other...
DailyMed label